Bristol Myers Squibb (CELG-RI) Buildings (2015 - 2026)
Bristol Myers Squibb (CELG-RI) reported Buildings of $7.5 billion for Q1 2026, up 12.74% year-over-year from $6.6 billion in Q1 2025, and up 2.97% quarter-over-quarter from $7.3 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Buildings (2015 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 12 years of Buildings data on file, last reported at $7.5 billion in Q1 2026.
- Buildings for Q1 2026 came in at $7.5 billion, up 12.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 billion (up 12.74% YoY), and the FY2025 annual result was $7.3 billion, up 10.47% from the prior year.
- Buildings grew to $7.5 billion in Q1 2026 per CELG-RI's latest filing, from $7.3 billion in the prior quarter.
- Over five years, Buildings peaked at $7.5 billion in Q1 2026 and troughed at $5.7 billion in Q2 2022.
- A 5-year average of $6.5 billion and a median of $6.5 billion in 2023 frame the typical range for Buildings.
- The sharpest annual moves came in 2022 and 2026: Buildings climbed 0.09% in 2022, then gained 12.74% in 2026.
- A 5-year view of Buildings shows it stood at $5.9 billion in 2022, then increased by 9.71% to $6.5 billion in 2023, then rose by 1.32% to $6.6 billion in 2024, then rose by 10.47% to $7.3 billion in 2025, then rose by 2.97% to $7.5 billion in 2026.
- Business Quant data shows CELG-RI's Buildings at $7.5 billion in Q1 2026, $7.3 billion in Q4 2025, and $7.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.49 Bn |
| Dec 31, 2025 | 7.27 Bn |
| Sep 30, 2025 | 7.12 Bn |
| Jun 30, 2025 | 6.86 Bn |
| Mar 31, 2025 | 6.64 Bn |
| Dec 31, 2024 | 6.58 Bn |
| Sep 30, 2024 | 6.47 Bn |
| Jun 30, 2024 | 6.67 Bn |
| Mar 31, 2024 | 6.55 Bn |
| Dec 31, 2023 | 6.50 Bn |
| Sep 30, 2023 | 6.28 Bn |
| Jun 30, 2023 | 6.04 Bn |
| Mar 31, 2023 | 5.99 Bn |
| Dec 31, 2022 | 5.92 Bn |
| Sep 30, 2022 | 5.75 Bn |
| Jun 30, 2022 | 5.74 Bn |
| Mar 31, 2022 | 5.94 Bn |
| Dec 31, 2021 | 5.90 Bn |
| Sep 30, 2021 | 5.74 Bn |
| Jun 30, 2021 | 5.71 Bn |